HRP20150177T1 - Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva - Google Patents

Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva Download PDF

Info

Publication number
HRP20150177T1
HRP20150177T1 HRP20150177AT HRP20150177T HRP20150177T1 HR P20150177 T1 HRP20150177 T1 HR P20150177T1 HR P20150177A T HRP20150177A T HR P20150177AT HR P20150177 T HRP20150177 T HR P20150177T HR P20150177 T1 HRP20150177 T1 HR P20150177T1
Authority
HR
Croatia
Prior art keywords
preparation
accordance
intended
cells
host
Prior art date
Application number
HRP20150177AT
Other languages
English (en)
Croatian (hr)
Inventor
Jennifer Lighter
Jason Fisher
Original Assignee
Mico Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mico Bio, Inc. filed Critical Mico Bio, Inc.
Publication of HRP20150177T1 publication Critical patent/HRP20150177T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20150177AT 2007-04-12 2008-04-11 Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva HRP20150177T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92330107P 2007-04-12 2007-04-12
PCT/US2008/060065 WO2008128065A2 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same
EP08745627.3A EP2144626B8 (en) 2007-04-12 2008-04-11 Tuberculosis vaccine and method of using same

Publications (1)

Publication Number Publication Date
HRP20150177T1 true HRP20150177T1 (hr) 2015-04-10

Family

ID=39523390

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150177AT HRP20150177T1 (hr) 2007-04-12 2008-04-11 Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva

Country Status (14)

Country Link
US (3) US8394389B2 (OSRAM)
EP (1) EP2144626B8 (OSRAM)
JP (2) JP5713672B2 (OSRAM)
AU (1) AU2008240181B2 (OSRAM)
CA (1) CA2682870C (OSRAM)
CY (1) CY1117290T1 (OSRAM)
DK (1) DK2144626T3 (OSRAM)
ES (1) ES2531018T3 (OSRAM)
HR (1) HRP20150177T1 (OSRAM)
HU (1) HUE024427T2 (OSRAM)
PL (1) PL2144626T3 (OSRAM)
PT (1) PT2144626E (OSRAM)
SI (1) SI2144626T1 (OSRAM)
WO (1) WO2008128065A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2144626E (pt) 2007-04-12 2015-03-03 Lighter Jennifer Vacina para a tuberculose e processo para o seu uso
WO2012137072A1 (en) 2011-04-06 2012-10-11 Biovaxim Limited Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans
US9839684B2 (en) 2011-04-06 2017-12-12 Biovaxim Limited Pharmaceutical compositions comprising inactivated HIV viral particles and non-pathogenic lactobacilli for the induction of antigen-specific immunotolerance
KR20140053887A (ko) * 2011-04-20 2014-05-08 미코 바이오, 인크. 면역 반응을 증진시키는 조성물 및 방법
ES2438690B1 (es) * 2012-06-15 2015-01-16 Fundació Institut Per A La Investigació En Ciències De La Salut "Germans Trias I Pujol" (Igtp) Unitat De Tuberculosi Experimental Micobacterias inactivadas para su uso por vía oral en la prevención de la tuberculosis
EP2679677A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US9388400B2 (en) 2012-06-29 2016-07-12 Lysando Ag Composition for use in mycobacteria diagnosis
EP2679232A1 (en) * 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria vaccination
KR101615186B1 (ko) 2014-03-07 2016-04-25 연세대학교 산학협력단 결핵 백신의 면역효과 증강용 조성물 및 면역효과 증진 방법
KR101631054B1 (ko) * 2015-12-31 2016-06-16 중앙대학교 산학협력단 마이코박테리아 유래 CFP-10 또는 Ag85B에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편
US10279031B2 (en) * 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
CN108743931B (zh) 2018-05-02 2022-08-16 成都威斯克生物医药有限公司 抗结核病疫苗及其制备方法和用途
US12491216B2 (en) 2018-12-04 2025-12-09 Neiker—Instituto Vasco De Investigacion Y Desarrollo Agrario, S.A. Immunostimulant for use against pathogens

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4724114A (en) 1984-04-23 1988-02-09 Kimberly-Clark Corporation Selective layering of superabsorbents in meltblown substrates
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
DE60226175T2 (de) * 2001-11-14 2009-07-09 Novavax, Inc. Mycobakterieller impfstoff
KR20050008453A (ko) 2002-03-08 2005-01-21 바쿠레시 마파탈 카마르 결핵 관리에 유용한 약제학적 조성물의 제조방법
EP2380589A3 (en) * 2005-06-23 2012-09-12 Statens Serum Institut Improved tuberculosis vaccines
PT2144626E (pt) 2007-04-12 2015-03-03 Lighter Jennifer Vacina para a tuberculose e processo para o seu uso

Also Published As

Publication number Publication date
WO2008128065A3 (en) 2008-12-18
US8932608B2 (en) 2015-01-13
EP2144626B8 (en) 2015-02-18
JP2015038130A (ja) 2015-02-26
JP2010523711A (ja) 2010-07-15
CA2682870C (en) 2016-08-09
US20150258187A1 (en) 2015-09-17
US20130273110A1 (en) 2013-10-17
EP2144626A2 (en) 2010-01-20
US20100112007A1 (en) 2010-05-06
PT2144626E (pt) 2015-03-03
AU2008240181B2 (en) 2014-01-09
ES2531018T3 (es) 2015-03-09
US9636391B2 (en) 2017-05-02
JP5713672B2 (ja) 2015-05-07
AU2008240181A1 (en) 2008-10-23
SI2144626T1 (sl) 2015-04-30
EP2144626B1 (en) 2014-12-03
DK2144626T3 (en) 2015-02-09
CA2682870A1 (en) 2008-10-23
CY1117290T1 (el) 2017-04-26
WO2008128065A2 (en) 2008-10-23
US8394389B2 (en) 2013-03-12
HUE024427T2 (en) 2016-01-28
PL2144626T3 (pl) 2015-09-30

Similar Documents

Publication Publication Date Title
HRP20150177T1 (hr) Cjepivo protiv tuberkuloze i postupak upotrebe tog cjepiva
TW200722101A (en) Novel composition
Sjölander et al. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses
EP2712625A3 (en) Vaccines comprising TB 10.4
MY126588A (en) Intranasal influenza virus vaccine
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
Lowell et al. Back to the future: immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
JP2018501322A5 (OSRAM)
RU2013119946A (ru) Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал
González-González et al. The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model
NZ630868A (en) Acellular pertussis vaccine
MY187472A (en) Multivalent vlp conjugates
WO2003007869A3 (en) Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
Raska et al. DNA vaccines for the induction of immune responses in mucosal tissues
Szachniewicz et al. Evaluation of PLGA, lipid-PLGA hybrid nanoparticles, and cationic pH-sensitive liposomes as tuberculosis vaccine delivery systems in a Mycobacterium tuberculosis challenge mouse model–A comparison
JP2010501595A5 (OSRAM)
AR038311A1 (es) Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
Wales et al. Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy
WO2006114680A3 (en) Vaccine adjuvants
WO2013142377A3 (en) Modified marek's disease virus, and vaccines made therefrom
Garcia-Contreras et al. Inhaled vaccines for the prevention of tuberculosis
Faisal Liposome adjuvants: Simultaneous induction of innate and adaptive immunity is key to success
Simon et al. Mucosal immunization and needle-free injection devices
AR046921A1 (es) Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes